AIDSinfo E-News: Offering HIV/AIDS Research, Clinical Trials, Prevention, and Treatment Information. |
AIDSinfo At-a-Glance Issue No. 33September 30, 2005 AIDSinfo.nih.gov is pleased to provide you with a weekly update of highlights about what has happened in the world of HIV/AIDS treatment, prevention, and research. We hope you find this encapsulated view of HIV/AIDS news useful. New Fact Sheet on Listing Drug Formulations for
Approved HIV Drugs
Check out AIDSinfo's newest fact sheet, “HIV Medications Available in Liquid, IV, Capsule, and Tablet.” This fact sheet was created by AIDSinfo staff as a result of the high volume of inquiries about available formulations for each approved HIV drug. It details most of the FDA approved, Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs) and Fusion inhibitors. To look at this fact sheet go to : http://aidsinfo.nih.gov/other/cbrochure/english/13_en.pdf
FDA Approves Liquid Formulation of
Emtriva
The U.S. Food and Drug Administration (FDA) approved the oral suspension formulation of Emtriva, making it available in pediatric dosage for infants over three months of age. To read the FDA press release for more information go to: http://aidsinfo.nih.gov/other/FDA_9_29_05.pdf
FDA Approves Generic HIV/AIDS Drug for Use in the
United States The U.S. Food and Drug Administration (FDA) announced the approval of generic versions of zidovudine (also known as AZT, ZDV, or Retrovir). This generic product can now be marketed here in the United States. To read the full FDA press release on this, go to: http://www.fda.gov/bbs/topics/NEWS/2005/NEW01232.html
|
|
You are currently subscribed to %%list.name%% as:
%%emailaddr%% Subscribe to AIDSinfo list serv here. |
Contact AIDSinfo Click on the Live Help button on the AIDSinfo home page
and communicate with the staff in “real time.” |